Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.
The company expects to generate free cash flow between $1.10 billion and $1.20 billion this year, compared with its earlier forecast of between $1.03 billion and $1.13 billion.
